In Paroxysmal Nocturnal Hemoglobinuria (PNH) a number of hematopoietic cells cannot place or maintain glycosylphosphatidylinositol (GPI)-anchored proteins on the cell surface. This could be a result of defective GPI anchor synthesis or attachment or an overactive phospholipase. Our laboratory has begun to characterize the GPI biosynthetic pathway in mammalian cells. Several biosynthetic intermediates, including the complete GPI core, have been identified using a combination of metabolic labeling and chemical/enzymatic tests. A three-step procedure has been developed to provide unequivocal definition of biosynthetic defects in the mutants. First, [3H]mannose was used to label intact cells to identify the mannosylated GPI intermediates. Second, UDP-N-acetyl-[3H]glucosamine was used to label a cell-free system to identify earlier defects. Third, a complementation test was used to classify the mutants into different complementation classes. Here, we propose to apply this technology to a panel of murine and human mutant cell lines. The detailed structures of key GPI intermediates will analyzed with a combination of chromatographic and spectroscopic procedures, taking advantage of the accumulation of relatively high concentrations of intermediates in some mutants as a result of biosynthetic block. Similar analysis will be applied to PNH neutrophils and to PNH T cell lines and EBV-transformed B cells to pin-point the biosynthetic defect. Our research will lead to a better understanding of the biology of the GPI anchor in health and disease.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL045851-02
Application #
3364917
Study Section
Pathobiochemistry Study Section (PBC)
Project Start
1991-02-01
Project End
1993-01-31
Budget Start
1992-02-01
Budget End
1993-01-31
Support Year
2
Fiscal Year
1992
Total Cost
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
02199
Stier, Sebastian; Cheng, Tao; Dombkowski, David et al. (2002) Notch1 activation increases hematopoietic stem cell self-renewal in vivo and favors lymphoid over myeloid lineage outcome. Blood 99:2369-78
Kito, K; Wada, H; Yeh, E T et al. (1999) Identification of novel isoforms of human RAD52. Biochim Biophys Acta 1489:303-14
Wada, H; Yeh, E T; Kamitani, T (1999) Identification of NEDD8-conjugation site in human cullin-2. Biochem Biophys Res Commun 257:100-5
Wada, H; Yeh, E T; Kamitani, T (1999) The von Hippel-Lindau tumor suppressor gene product promotes, but is not essential for, NEDD8 conjugation to cullin-2. J Biol Chem 274:36025-9
Gong, L; Yeh, E T (1999) Identification of the activating and conjugating enzymes of the NEDD8 conjugation pathway. J Biol Chem 274:12036-42
Gong, L; Li, B; Millas, S et al. (1999) Molecular cloning and characterization of human AOS1 and UBA2, components of the sentrin-activating enzyme complex. FEBS Lett 448:185-9
Kamitani, T; Kito, K; Nguyen, H P et al. (1998) Identification of three major sentrinization sites in PML. J Biol Chem 273:26675-82
Kamitani, T; Nguyen, H P; Kito, K et al. (1998) Covalent modification of PML by the sentrin family of ubiquitin-like proteins. J Biol Chem 273:3117-20
Patel, S S; Thiagarajan, R; Willerson, J T et al. (1998) Inhibition of alpha4 integrin and ICAM-1 markedly attenuate macrophage homing to atherosclerotic plaques in ApoE-deficient mice. Circulation 97:75-81
Wada, H; Kito, K; Caskey, L S et al. (1998) Cleavage of the C-terminus of NEDD8 by UCH-L3. Biochem Biophys Res Commun 251:688-92

Showing the most recent 10 out of 28 publications